PMID: 26350339Sep 10, 2015Paper

Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

CNS & Neurological Disorders Drug Targets
Ligia Mendes SoaresRubia Maria Weffort de Oliveira

Abstract

Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

Citations

Jul 5, 2017·Canadian Journal of Physiology and Pharmacology·Mohamed BejaouiHassen Ben Abdennebi
Dec 22, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wesam S AhmedKabir H Biswas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Related Papers

Vestnik Rossiĭskoĭ akademii meditsinskikh nauk
V I Skvortsova
Best Practice & Research. Clinical Anaesthesiology
Christian Werner
Molecular Neurobiology
R I GrundyM Beltramo
© 2021 Meta ULC. All rights reserved